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Abstract
Background—Genome-wide association studies (GWAS) have identified loci associated with
ischemic stroke (IS) and cardiovascular disease (CVD) in European-descent individuals, but their
replication in different populations has been largely unexplored.
Methods and Results—Nine single-nucleotide polymorphisms (SNPs) selected from GWAS
and meta-analyses of stroke and 86 SNPs previously associated with myocardial infarction and
CVD risk factors including blood lipids (HDL, LDL, triglycerides), type 2 diabetes and body mass
index were investigated for associations with incident IS in European Americans (EA) N=26,276;
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African Americans (AA) N=8970; and American Indians (AI) N= 3570 from the Population
Architecture using Genomics and Epidemiology Study. Ancestry-specific fixed effects meta-
analysis with inverse variance weighting was used to combine study-specific log hazard ratios
from Cox proportional hazards models. Two of 9 stroke SNPs (rs783396 and rs1804689) were
associated with increased IS hazard in AA; none were significant in this large EA cohort. Of 73
CVD risk factor SNPs tested in EA, two (HDL and triglycerides SNPs) were associated with IS. In
AA, SNPs associated with LDL, HDL and BMI were significantly associated with IS (3 of 86
SNPs tested). Out of 58 SNPs tested in AI, one LDL SNP was significantly associated with IS.
Conclusions—Our analyses showing lack of replication in spite of reasonable power for many
stroke SNPs and differing results by ancestry highlight the need to follow-up on GWAS findings
and conduct genetic association studies in diverse populations. We found modest IS associations
with BMI and lipids SNPs, though these findings require confirmation.
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Introduction
Family studies suggest that stroke has a substantial genetic component.1, 2 To date, a small
number of genetic variants associated with stroke have been identified in genome-wide
association studies (GWAS). These studies were conducted in largely European-descent
populations, though the burden of stroke is higher in minority populations in the US.3 Stroke
incidence and mortality in African Americans and stroke incidence in American Indians are
nearly twice that of European-Americans.4
Stroke is a heterogeneous disease consisting of several distinct subtypes, each having their
own etiologies.5 Ischemic stroke, the most common subtype accounting for ~87% of
strokes,6 shares many risk factors with cardiovascular disease due to a common etiological
factor, atherosclerosis.7 Shared risk factors for these diseases may also encompass genetic
factors, such as gene variants involved in atherosclerosis. We sought to replicate
associations between incident ischemic stroke and ischemic stroke SNPs identified in
previous genome-wide association (GWA) or meta-analysis studies of European populations
in a large sample of European Americans (EA), and investigated whether associations were
consistent for African Americans (AA). Furthermore, we tested whether SNPs associated
with myocardial infarction (MI) and cardiovascular disease risk factors (blood lipids, type 2
diabetes [T2D] and body mass index [BMI]) are also associated with the incident ischemic
stroke hazard in EA, AA and American Indians (AI) from the Population Architecture using
Genomics and Epidemiology (PAGE)8 Study.
Methods
As part of the PAGE Study, four cohort studies with adjudicated stroke data were included
in these analyses: Atherosclerosis Risk in Communities (ARIC),9 Cardiovascular Health
Study (CHS),10 Strong Heart Study (SHS),11 and Women’s Health Initiative (WHI).12
Participants were censored at the first incident ischemic stroke event and individuals with a
history of stroke or transient ischemic attack at baseline were excluded. All studies were
approved by local institutional review boards and all participants gave informed consent.
The study populations are briefly described in Table 1 and below.
The Women’s Health Initiative (WHI) recruited 161,838 postmenopausal women aged 50–
79 yrs. old from 40 clinical centers in the US between 1993 and 1998.12, 13 WHI consists of
an observational study, two clinical trials of postmenopausal hormone therapy (estrogen
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alone or estrogen plus progestin), a calcium and vitamin D supplement trial, and a dietary
modification trial. A subset of the WHI cohort, n=21,000, were selected for PAGE
genotyping and for inclusion in these analyses. Women were selected based on self-reported
history of disease, incident event outcomes, DNA availability and consent, and racial/ethnic
diversity. In the association analyses, inverse-probability weighting was used to account for
this non-random sampling. Sample weights ranged from 1 to 60.4. DNA was extracted from
blood samples collected at baseline. Incident stroke events were identified by semi-annual
questionnaires and adjudicated following medical record review.
The Atherosclerosis Risk in Communities (ARIC) Study is a bi-racial population-based
cohort recruited from four U.S. communities: Forsyth County, North Carolina; Jackson,
Mississippi; suburban areas of Minneapolis, Minnesota; and Washington County, Maryland,
USA.9 The 15,792 men and women in ARIC, including 11,478 non-Hispanic white
participants, were between 45-64 years of age at baseline and were followed up for possible
stroke events (http://www.cscc.unc.edu/aric/) through annual phone interviews, follow-up
examinations, community hospital surveillance, and death certificates. Reported
hospitalizations led to screening and, if suitable, to medical record abstraction. Potential
stroke events were selected for medical records abstraction if the discharge diagnosis
included a cerebrovascular disease code (International Classification of Diseases, 9th
Revision, codes 430 to 438), if a cerebrovascular procedure was mentioned in the discharge
summary, or if the CT or MRI report showed evidence of acute cerebrovascular disease.14
All suspected events were classified by computer algorithm and also by an expert physician
reviewer, blinded to the automated results. A second physician reviewer adjudicated
disagreements between the computer and the initial reviewer.
The Cardiovascular Health Study (CHS) is a population-based longitudinal study of risk
factors for cardiovascular disease in adults 65 years of age or older.15 A total of 5,201
predominantly European Americans were recruited in 1989-1990 from random samples of
Medicare eligibility lists at four field centers (Forsyth County, North Carolina; Sacramento
County, California; Washington County, Maryland; Pittsburgh, Pennsylvania), followed by
an additional 687 African Americans recruited in 1992-1993 (total n=5,888). CHS
participants completed standardized clinical examinations and questionnaires at study
enrollment and at up to nine annual follow-up visits and are being followed for clinical
events. Incident strokes were identified at semi-annual exams and through community
surveillance and adjudicated by neurologists.10
Funded by the National Heart, Lung, and Blood Institute, the Strong Heart Study (SHS) is a
population-based longitudinal study of 4,549 American Indian men and women recruited
from 13 communities and from centers located in 3 US geographic areas
(http://strongheart.ouhsc.edu/). SHS participants aged 45-74 years underwent a baseline
(1989-1991) and then two follow-up (1993-1995 and 1996-1999) examinations. Incident
ischemic stroke events were identified at yearly interviews and/or examinations and
adjudicated by neurologists.
SNPs were identified using the National Human Genome Research Institute’s Catalog of
Published GWAS16, a comprehensive database of GWA investigations. GWAS SNPs and
well-replicated SNPs from meta-analyses associated with stroke (n=9), myocardial
infarction/coronary heart disease (CHD) (n=16), T2D (n=19), high density lipoprotein
cholesterol (HDL) (n=17), low density lipoprotein cholesterol (LDL) (n=16), triglycerides
(TG) (n=4) and BMI (n=14) for a maximum total of 86 SNPs as of Jan 1, 2009 were
genotyped by each study in PAGE (see Table 2 and Supplemental Tables 1-3 for lists of
included SNPs).17181920 PAGE quality control measures called for exclusion of SNPs with
call rates <95% or with <98% concordance among duplicate samples, and exclusion of
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individuals with call rates<95%, though WHI used more stringent criteria. For SNPs in
ancestry-specific Hardy Weinberg disequilibrium (p<5×10−5), intensity plot clustering was
reviewed manually and SNPs were excluded if clustering was judged to be poor. SNPs that
were successfully genotyped, passed quality control measures and were available in at least
two PAGE studies are included in the EA and AA analysis. For the AI analysis, all CVD
risk factor SNPs passing QC in SHS were tested; however, the 9 stroke SNPs were not
genotyped.
Genotype data were coded assuming additive genetic models, with each SNP coded as a
count of the variant alleles (0, 1, or 2), unless otherwise specified. Ancestry-stratified Cox
proportional hazards models were minimally adjusted for age, sex and study site (as
appropriate in each sub-study). African American models were additionally adjusted for
global ancestry to account for population substructure in WHI and ARIC; in CHS, study site
was used as a proxy for ancestry. In SHS, AI models were adjusted for self-reported AI
ancestry obtained by questionnaire. Study-specific results (or in the case of SHS, site-
specific results) were combined in a fixed effects meta-analysis with inverse variance
weighting using METAL.21 Per allele hazard ratios (HR) and 95% confidence intervals
(95%CI) from the meta-analysis are reported. Heterogeneity for the SNP effects across
PAGE cohorts was assessed using I2 and the Q-test statistic.22 Aggregate data from the
meta-analysis and individual tests of association from each PAGE study will be made
available via dbGaP.23 Results are presented unadjusted for multiple testing with
presentation of the multiple testing implications for interpretation in the discussion. Power
calculations were performed using Quanto24 assuming unrelated participants, population
risk of ischemic stroke=0.04, additive genetic models (or dominant or recessive models as
appropriate based on prior reports), unmatched case-control study design, effect size equal
to the 95% CI closest to the null based on prior reports in European-descent populations, and
the average ancestry-specific allele frequencies and number of incident ischemic stroke
cases listed in Table 1. Power estimates for GWAS-identified stroke SNPs were also
corrected for ‘winner’s curse’25 bias using the above assumptions with the exception of the
effect size, which was based on bias-reduced estimates obtained using the method detailed
in Zhong and Prentice.26 The ‘winner’s curse’ refers to the ascertainment bias affecting gene
association results; genetic associations which are significant in the initial study (GWAS)
may be overestimated, while other associations (potentially underestimated) are less likely
to be published and selected for follow-up. Because the ‘winner’s curse’ results are inflated,
they can be difficult to replicate in follow-up studies, and if used for power calculations, can
result in inflated power estimates. Zhong and Prentice26 propose a method using conditional
maximum likelihood estimation and quartile-based confidence interval procedures to
estimate bias-corrected betas and selection-adjusted confidence intervals. We contrast power
calculations using these bias-adjusted estimates with calculations using the original GWAS
estimates.
Results
During follow-up, there were a total of 3,239 incident ischemic strokes in EA, 655 in AA
and 163 in AI. A total of 9 stroke SNPs were investigated for their associations with IS in
EA and AA (genotypes were unavailable in AI). None of these SNPs was significantly
associated with risk of incident ischemic stroke in EA (Table 2). In AA, two SNPs
(rs783396 and rs1804689) were significantly associated with ischemic stroke at p<0.05. The
original reports for 3 of the 9 stroke SNPs described associations using dominant and
recessive models rather than additive models; when we modeled SNPs similarly, results
from the meta-analyses in AA and EA changed only slightly and remained non-significant
(data not shown). In sensitivity analyses, using a smaller subset of the WHI EA women
(n=1205) having more detailed stroke subtype information, we tested for stroke SNP
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associations with large artery (n=189), cardioembolic (n=531) and lacunar strokes (n=485).
Rs10486776 was significantly associated with large artery ischemic stroke, p=0.005, and
rs7506045 was significantly associated with cardioembolic ischemic stroke, p=0.027; no
other significant associations with ischemic stroke subtypes were found.
In EA, a total of 73 CVD risk factor SNPs were investigated (Supplemental Table 1); of
these, the HDL SNP rs2156552 (p=0.006) and the triglycerides SNP rs2954029 (p=0.048)
were significantly associated with ischemic stroke (Table 3). In AA, we tested a total of 86
CVD risk factor SNPs (Supplemental Table 2); three SNPs were associated with ischemic
stroke, the HDL SNP rs1800961 (p=0.0006), the LDL SNP rs6544713 (p=0.022) and the
BMI SNP rs11084753 (p=0.024) (Table 3). In American Indians (AI), a smaller subset of 58
CVD risk factor SNPs were tested (Supplemental Table 3). Rs754523, a SNP previously
associated with LDL levels, was associated with ischemic stroke, p=0.0026 (Table 3).
Discussion
In this analysis of multi-ethnic populations from four large cohort studies, we followed up
on previous gene association study findings for ischemic stroke in diverse ancestral groups
and explored whether GWAS SNPs for CVD risk factors are also associated with ischemic
stroke. While several SNPs have been previously associated with ischemic stroke, including
exonic variants in the MTHFR, AIM1 and F5 genes, we were unable to replicate these
associations in our large EA population. Interestingly, two SNPs were significantly
associated with incident ischemic stroke in AA, rs783396 and rs1804689. Located in an
exon of the absent in melanoma-1 (AIM1) gene whose expression is associated with
melanoma tumor suppression, rs783396-A (Ala->Glu) is a non-synonymous variant. The
variant was previously associated with an increased risk of ischemic stroke in EA19 with an
OR=5.79 (95% CI:2.66-12.59), which is consistent with our finding of an increased risk of
stroke in AA. However, it is possible that the original estimate was inflated due to
ascertainment bias termed the winner’s curse.25 Indeed, adjustment for winner’s curse bias
greatly attenuated the original estimates as well as our hypothetical power to replicate them.
Rs1804689 (A allele) in the 5′ UTR of the HPS1 gene was previously associated with an
increased risk of ischemic stroke in CHS EA20, but in our AA population (ARIC and WHI)
it was associated with a significantly reduced risk of ischemic stroke. Different patterns of
linkage disequilibrium in this gene region could potentially explain these contradictory
findings; accordingly, the average allele frequencies for the PAGE AA (0.14) and EA (0.31)
are markedly different.
Since the ischemic stroke subtype may be heterogeneous in its etiology and thus have
different risk factors27, we explored ischemic stroke subtypes in a smaller subset of WHI
women having more detailed data in sensitivity analyses. We identified 2 SNPs associated
with large artery and cardioembolic stroke in EA—though interestingly, these SNPs were
not strongly associated with either ischemic stroke subtype in the original GWAS.19 One
important difference is that our analyses were conducted in EA women only, while the
GWAS included both sexes. However, both subtype analyses have small sample sizes which
may be more susceptible to spurious results.
Given our lack of replication along with our high power to replicate the lower confidence
limit of previously reported or bias-adjusted effect sizes for almost half of the stroke SNPs
in EA, we could suggest that previous findings may reflect type 1 error. Indeed, several
others have commented on the lack of reproducibility of stroke-gene associations28-30 citing
low power, study design issues, population stratification and study heterogeneity as potential
causes. Several of the previous stroke studies were conducted in the case-control setting and
may be prone to potential selection and survival biases, in contrast to our analyses which
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were conducted in cohorts with many years of longitudinal follow-up and which also
included some fatal stroke cases. Yet, these explanations do not appear to account for the
differences in population-specific findings in our analysis. A potential explanation for the
differences in population-specific results is gene-environment interaction. It might be that
these SNPs exert their effects most strongly in the presence of environmental or host risk
factors which may differ between studies or between ancestry groups in the same study.
Comparison of the prevalence of stroke risk factors reveals that BMI tends to be higher and
T2D is more common in PAGE AA and AI than EA; hypertension is also much more
common in AA than in the other groups. However, we saw the most suggestive findings for
the lipids SNPs; the use of lipid lowering medications at baseline and during early follow-up
was low in all groups since recruitment for each of the studies primarily occurred before the
introduction and widespread use of the recent generation of lipid-lowering medications.
Although ischemic stroke and MI/CHD share many risk factors, SNPs associated with MI/
CHD traits were not significantly associated with incident ischemic stroke in our population.
The 9p21 locus has been previously associated with coronary heart disease31 and myocardial
infarction32 in multiple GWAS, although findings for stroke outcomes have been mixed. A
recent study33 attributes these mixed results to stroke subtype heterogeneity and reported
that the 9p21 locus was significantly associated with large artery ischemic stroke, which is
consistent with prior associations for atherosclerotic disease of the coronary arteries and
abdominal aorta.32, 34 Chromosome 9p21 variants, rs10757278, rs1333049, rs2383206,
rs2383207 and rs4977574 were included among the MI/CHD 9p21 SNPs we tested, but in
sensitivity analyses of ischemic stroke subtypes, none were significantly associated with
large artery (p=0.47-0.61) or cardioembolic (p=0.06-0.24) stroke in WHI EA. However, all
of these 9p21 variants were modestly associated with small vessel (lacunar) ischemic stroke
(p=0.04-0.07) in EA. While inconsistent with the previous report, this finding is exploratory
and was conducted in a small sample of postmenopausal women.
Overall, few CVD risk factor SNPs, including other 9p21 variants, were associated with risk
of ischemic stroke in our study, with the exception of 5 lipid SNPs and 1 BMI SNP. In AA,
an LDL SNP (rs6544713) and an HDL SNP (rs1800961) were significantly associated with
ischemic stroke. The LDL SNP was also associated with increased LDL concentrations in
all three ancestral groups in PAGE, while the HDL SNP, a non-synonymous variant in the
hepatocyte nuclear factor 4 alpha gene, was associated with lower HDL levels in EA and AI,
and showed a similar trend in AA that was not significant.35 These findings suggesting
SNP-related lipid level differences are consistent with the increased risk of stroke that we
find in our analysis, i.e. SNPs associated with adverse lipid concentration trends are
associated with increased risk of stroke. Similarly, in AI, the APOB SNP rs754523-T was
associated with a reduced risk of stroke; this SNP has been also been associated with
reduced LDL levels in the PAGE study.35 EA findings include rs2156522 which was
significantly associated with ischemic stroke; this SNP has been previously associated with
HDL concentrations in PAGE EA, but not in PAGE AA.35 Conversely, the triglycerides
SNP rs2954029 was significantly associated with an increased risk of stroke in EA, but
slightly reduced triglyceride levels, which is contrary to what we might expect. And finally,
the BMI SNP rs11084753, was associated with ischemic stroke in AA, but was not
significantly associated with BMI in any of the PAGE race/ethnicity groups (Fesinmeyer
MD, et al., manuscript submitted to Obesity, 2011). These lipid and BMI SNP findings were
generally not consistent between ancestral groups. In part, these differences may be
explained by different linkage disequilibrium patterns across the loci in the different
population groups. This scenario would be expected if the originally identified SNPs act as
tags for the functional variant and the tags do not extend across race/ethnicity groups due to
differences in linkage disequilibrium. Indeed, the majority of SNPs identified in GWAS are
noncoding, located in intergenic or intronic regions,16 although our non-synonymous HDL
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SNP (rs1800961) is a notable exception. This SNP is also interesting because it is in a gene,
hepatocyte nuclear factor 4 alpha (HNF4A), with potential pleiotropic effects. HNF4A
variants have been associated with lower HDL levels, as well as with Type 2 diabetes and
with levels of the coagulation factor, Factor VII, suggesting that this gene is involved in
multiple pathways relevant to the stroke outcome.
Potential limitations of this study include study heterogeneity, lack of detailed ischemic
stroke subtype information on the entire population and reduced power to detect modest
effect sizes in the smaller American Indian population and for a number of SNPs in EA and
AA. Our analysis of CVD risk factor SNPs was exploratory and with the exception of the
HDL SNP rs1800961 in AA, our findings were not statistically significant after Bonferroni
correction for multiple testing and thus should be interpreted cautiously until confirmed. We
tested for study heterogeneity in the meta-analysis and also assessed the magnitude of
heterogeneity using I2, but these tests may be less robust when small numbers of sub-studies
are analyzed36, such as in our case. The significant SNPs we report did not show significant
evidence of study heterogeneity; but it is possible that heterogeneity may have reduced our
power to detect significant associations for other SNPs. In general, allele frequencies were
consistent between the different studies for the EA and AA populations, though more
heterogeneity was seen for the AI, likely due to differing levels of admixture at the different
regional sites in SHS. Additionally, we report power estimates adjusted for the ‘winner’s
curse’ bias which tend to be more conservative than the naïve power estimates. Effect
estimates (and power) for several SNPs dropped substantially when accounting for this bias
suggesting that replication of these GWAS SNPs will be difficult in even large populations
such as the PAGE EA with more than 3200 ischemic strokes.
In spite of these limitations, our study includes large numbers of ancestrally diverse
individuals with adjudicated ischemic stroke outcomes, standardized methods and long
follow-up. Much of our sample is population-based and not subject to biases that might be
present in hospital-based case-control studies of stroke.
Conclusions
As fine-mapping and re-sequencing studies begin to investigate GWAS findings in more
detail, data regarding GWAS SNP replication in independent samples and across different
ancestry/ethnicity groups will be increasingly important for use in prioritizing SNPs for
follow-up37 and for enhancing our understanding of population differences in common
diseases. Our study contributes information about the reproducibility and magnitude of prior
GWAS-identified SNPs for ischemic stroke. While none replicated in our EA PAGE
population, two associations did generalize to AA. Furthermore, in analyses investigating
CVD pleiotropy for largely GWAS-based SNPs, we identified additional CVD risk factor
SNPs which may also be associated with stroke in diverse US ancestral/ethnic groups,
including AA and AI who are at high risk of this common disease.
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Recent genome-wide association studies (GWAS) have identified a number of genetic
variants associated with stroke and cardiovascular disease (CVD). However, data
regarding GWAS variant replication in independent samples and across different
ancestry/ethnicity groups are lacking but are important for prioritizing genetic variants
for translational research and for furthering our understanding of population differences
in complex diseases such as stroke. We sought to replicate previously identified single
nucleotide polymorphisms (SNPs) associated with ischemic stroke in GWAS and meta-
analyses using a large, well-characterized, multi-ethnic population. In addition, we tested
whether SNPs previously associated with CVD risk factors were also associated with
ischemic stroke. In spite of reasonable power, we did not replicate several of the previous
stroke findings in European descent individuals, but did identify associations in African
Americans for two SNPs in the AIM1 and HPS1 genes. In exploratory analyses
investigating CVD, we identified additional CVD risk factor (lipids and body mass
index) SNPs which may be associated with stroke in diverse US ancestral groups,
including African Americans and American Indians who are at high risk of stroke. Our
findings highlight the importance of replication and consideration of power in genetic
studies and support the investigation of non-European descent populations for identifying
genetic factors associated with complex disease.
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